Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Starting treatment news


From To
Issue Brief: Suboptimal Immune Recovery on Antiretroviral Therapy

A subset of people on ART experience limited or no recovery of CD4+ T cell counts despite achieving and maintaining undetectable HIV viral loads, and these individuals have an elevated risk of illness and death compared with counterparts who obtain greater CD4+ T cell gains.

06 March 2018
An Exciting Act II for the Study That Proved Treating HIV Early Is Best

With a grant to follow their large study population through 2021, researchers hope to gain vital new insights about HIV infection.

25 February 2018
Study finds more than half of patients worldwide don’t access HIV treatment until immune systems are severely compromised

Data from nearly a million patients starting treatment for HIV across the world over the last decade shows 55 percent of them accessed antiretroviral treatment only after their immune cell — or CD4 — counts had dropped below 200, leaving them extremely vulnerable to illnesses and infections.

02 February 2018
Science Speaks
GlaxoSmithKline Projects Tough Environment for Triumeq and Tivicay

GlaxoSmithKline is witnessing increased demand for Tivicay as compared to Triumeq. Approximately 40% to 45% of the prescribed Tivicay is used by physicians with Gilead Sciences’ Tenofovir alafenamide (or TAF) therapy, Descovy. The company expects increased competition for its dolutegravir franchise after the launch of Gilead Sciences’ (GILD) integrase inhibitor, bictegravir.

01 February 2018
Market Realist
China Introduces Low-Cost, Single-Pill HIV Treatment

Five months after receiving approval from the China Food and Drug Administration, British pharmaceutical giant GlaxoSmithKline (GSK) on Saturday introduced its market-leading antiretroviral drug Triumeq, which contains three active ingredients in a single pill.

24 January 2018
Sixth Tone
Immediate HIV Treatment Has Little Impact on Risk of Future Drug Resistance

Starting antiretroviral therapy (ART) immediately rather waiting until a person's CD4 count falls below 500 cells/µL has almost no impact on the person's risk of developing antiretroviral resistance over the next seven years, according to a study published online in the journal AIDS. In this 51,000-person analysis, the impact of immediate ART on acquired drug resistance disappeared almost completely among people starting treatment in 2005 or later.

07 January 2018
The Body Pro
NHS England have announced funding for immediate antiretroviral treatment for HIV patients

NHS England has announced that it has agreed that HIV antiretroviral medication will be provided to patients immediately once someone is diagnosed.

19 December 2017
Gay Times
Who Resists Starting ART Therapy for HIV?

The study found that the demographic characteristics of patients who failed to initiate ART within 2 years of entering care were not as important as clinical factors. Higher CD4 count, lower viral load, and a prevalent AIDS diagnosis were clinical characteristics associated with delayed ART initiation.

07 September 2017
MD Mag
Globally, People With HIV Are Starting Treatment Earlier

But the median CD4 count at treatment start is below 350, which means work is needed to catch up to World Health Organization guidelines.

21 August 2017
Terrence Higgins Trust and BHIVA advise on the use of generic HIV antiretroviral therapy

We believe that people living with HIV should be at the heart of decisions made about their care. Therefore decisions around switching to generic HIV medication should be based on a full discussion between a person living with HIV and their HIV clinician.

16 August 2017
Terrence Higgins Trust
← First12345...17Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.